LS-P-GO44479

LS-P-GO44479: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran plus Atezolizumab and mFolfirinox versus mFolfirinox Alone in Patients with Respected Pancreatic Ductal Adenocarcinoma
Status:

Open

Trial Type:

Contact:

Dr. Alex Raufi
araufi2@lifespan.org